Latest Commercialisation News

Page 16 of 239
Clarity Pharmaceuticals is approaching pivotal Phase III readouts for its prostate cancer imaging agent, backed by AUD178.3 million in liquid assets. The radiopharmaceutical developer remains deeply loss-making, but expanded manufacturing capacity and early clinical signals are pulling its commercial ambitions into sharper focus.
Victor Sage
Victor Sage
30 Sept 2026
Verity Resources has expanded its Monument gold story in Western Australia, but the explorer’s stronger resource base sits alongside a sharply higher annual loss, A$4.67 million operating cash outflow and a material uncertainty over its ability to continue as a going concern. The company finished FY2026 with A$1.05 million in cash and more than A$2.39 million of exploration commitments due within a year.
Maxwell Dee
Maxwell Dee
30 Sept 2026
1414 Degrees reported a wider FY2026 loss, falling cash reserves and a material uncertainty over its ability to continue as a going concern. The company is nevertheless pressing ahead with SiNTL battery commercialisation, a proposed 1 GW data centre precinct and full ownership of Aurora.
Victor Sage
Victor Sage
30 Sept 2026
Surefire Resources has flagged a material uncertainty over its ability to continue as a going concern after reporting a $2.07 million annual loss and $1.30 million in operating cash outflows. The company is advancing Victory Bore and Yidby, but both projects remain tied to funding, approvals and further execution.
Maxwell Dee
Maxwell Dee
30 Sept 2026
Ridley Corporation’s first full reporting year with the Incitec Pivot Fertilisers distribution business produced a sharp lift in underlying earnings and cash flow, despite a steep fall in statutory profit after a $31.8 million NovaqPro impairment. Management expects earnings growth across all three segments in FY27, but the enlarged group now carries significantly more debt and integration work.
Victor Sage
Victor Sage
30 Sept 2026
H3 Energy has consolidated ownership of its Alinya hydrogen and helium project and reframed Warro as a potential commercial gas development, but its annual report warns that funding remains critical. The company ended FY2026 with A$900,434 in cash, net liabilities of A$551,671 and a material uncertainty over its ability to continue as a going concern.
Maxwell Dee
Maxwell Dee
30 Sept 2026
Papyrus Australia has produced a second batch of TBS board samples, expanded pulp capacity in Adelaide and secured additional funding as it moves towards commercial supply. The progress comes with testing still incomplete and an estimated 4.87 months of funding available.
Victor Sage
Victor Sage
30 Sept 2026
AnteoTech has set sales conversion as its FY2027 priority after FY2026 sales revenue slipped to A$460,397, while operating expenses fell sharply and cash stood at A$11.2 million. The battery materials and life sciences company says customer evaluations and partnership discussions are building, but most opportunities remain short of recurring commercial revenue.
Victor Sage
Victor Sage
30 Sept 2026
Li-S Energy’s lithium-sulfur battery powered the Pegasus drone through an almost two-hour Queensland flight covering more than 75 kilometres. The result strengthens the technology’s aviation credentials, but the partners are still assessing commercialisation rather than announcing sales.
Victor Sage
Victor Sage
30 Sept 2026
Ocean Sciences delivered a sharp increase in seaweed revenue during FY2026, but the audited report also records a A$1.612 million continuing-operations loss, A$2.319 million operating cash outflow and material uncertainty over its ability to continue as a going concern. The renamed ASX-listed group is now seeking up to A$3 million while building out its Indonesian platform.
Ada Torres
Ada Torres
29 Sept 2026
Rhythm Biosciences has moved ColoSTAT and geneType into commercial use, recording its first sales during FY2026. But with sales revenue of just $85,339, a $5.93 million loss and an auditor-flagged going-concern uncertainty, the next phase will be judged on cash generation and repeat adoption.
Victor Sage
Victor Sage
29 Sept 2026
AnteoTech has received $1.905 million from the Australian R&D Tax Incentive, providing fresh cash for its battery materials and life sciences commercialisation efforts. The rebate relates to eligible research conducted during the 2026 financial year.
Sophie Babbage
Sophie Babbage
29 Sept 2026

Browse the archive

Full archive